Trial Profile
A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current Management
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Pegvaliase (Primary)
- Indications Phenylketonuria
- Focus Registrational; Therapeutic Use
- Acronyms OPTIC Study
- Sponsors BioMarin Pharmaceutical
- 27 Jul 2019 Trial has been discontinued in Netherlands, according to European Clinical Trials Database record.
- 22 Nov 2018 New trial record